Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Low-dose Ticagrelor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with coronary artery disease~Exclusion Criteria:~* younger than 18 years of age;~* anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;~* previous or current treatment with any other potentially confounding drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ticagrelor 45mg bidpo. (Type: EXPERIMENTAL): To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
- ticagrelor 90mg qdpo. (Type: EXPERIMENTAL): To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
- ticagrelor 90mg bidpo. (Type: ACTIVE_COMPARATOR): To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
- clopidogrel 75mg qdpo. (Type: ACTIVE_COMPARATOR): To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).